FDA approves Nurtec ODT to treat acute migraine. - Biohaven
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rayvow (Reyvow in US), intended for the treatment of migraine.
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for atogepant (Quilpta) to the FDA to support the preventive treatment of chronic migraine in adults.